- Brain health company IXICO posts a pre-tax loss of £772,000 for the six months to the end of March - down from £1.5m a year ago.

Revenues rose to £1.6m from £1.2m and total operating expenses fell to £2.1m from £2.5m.

Chief executive Derek Hill said: "We have delivered strong growth in our business and made good progress in executing important strategic developments during the period.

"Our digital technology platforms are opening up new, high value commercial opportunities with existing and new customers in dementia and increasingly, other diseases. The marked top-line growth we have reported arises from both expansion of our clinical trials business and initial contracts from the pharmaceutical sector for our digital healthcare platform. We expect to maintain this momentum and to grow our digital healthcare revenue moving forward.

"We look forward to building on this progress to take IXICO into the next phase of its corporate development. We continue to explore opportunities to build critical mass through further partnerships, product licencing and potential merger and acquisition activities."

At 9:47am: [LON:IXI] IXICO plc share price was +1p at 29p

Story provided by